Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (GD therapy) for high-grade soft tissue sarcomas.
Not Applicable
- Conditions
- High-grade soft tissue sarcomas
- Registration Number
- JPRN-UMIN000015120
- Lead Sponsor
- Tokyo Metropolitan Komagome Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with double cancer 2. Patients who took Kampo within 4 weeks 3. Patients with any other severe diseases 4. Pregnat patients 5. Other exclusionary comobidity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ausea, emesis and anorexia (CTCAE ver4.0), EORTC QLQ-C30(version3)
- Secondary Outcome Measures
Name Time Method